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Introduction: Cardiovascular disease (CVD) is the leading cause of mortality worldwide
and is the leading cause of death in the US. Lipid dysregulation is a well-known precursor
to metabolic diseases, including CVD. There is a growing body of literature that suggests
MRI-derived epicardial fat volume, or epicardial adipose tissue (EAT) volume, is linked to
the development of coronary artery disease. Interestingly, epicardial fat is also actively
involved in lipid and energy homeostasis, with epicardial adipose tissue having a greater
capacity for release and uptake of free fatty acids. However, there is a scarcity of
knowledge on the influence of plasma lipids on EAT volume.
Aim: The focus of this study is on the identification of novel lipidomic species associated
with CMRI-derived measures of epicardial fat in Mexican American individuals.
Methods: We performed lipidomic profiling on 200 Mexican American individuals.
High-throughput mass spectrometry enabled rapid capture of precise lipidomic profiles,
providing measures of 799 unique species from circulating plasma samples. Because of
our extended pedigree design, we utilized a standard quantitative genetic linear mixed
model analysis to determine whether lipids were correlated with EAT by formally testing
for association between each lipid species and the CMRI epicardial fat phenotype.
Results:
After correction for multiple testing using the FDR approach, we
identified 135 lipid species showing significant association with epicardial fat. Of
those, 131 lipid species were positively correlated with EAT, where increased
circulating lipid levels were correlated with increased epicardial fat. Interestingly,
the top 10 lipid species associated with an increased epicardial fat volume were
from the deoxyceramide (Cer(m)) and triacylglycerol (TG) families. Deoxyceramides
are atypical and neurotoxic sphingolipids. Triacylglycerols are an abundant lipid
class and comprise the bulk of storage fat in tissues. Pathologically elevated TG
and Cer(m) levels are related to CVD risk and, in our study, to EAT volume.
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Conclusion: Our results indicate that specific lipid abnormalities such as enriched
saturated triacylglycerols and the presence of toxic ceramides Cer(m) in plasma of our
individuals could precede CVD with increased EAT volume.
Keywords: cardiovascular disease, lipidomic profiles, epicardial fat volume, Mexican Americans, CMRI

INTRODUCTION

metabolism and MeD, and identifying pathways representing
potential therapeutic targets not seen with studies of traditional
lipids (19).
Intermediate phenotypes such as those derived by CMRI
and lipid profiling lie closer to the genomic level and the
causal action of genes. Organ-specific adiposity has renewed
growing interest in that and contributes to the pathophysiology
of cardiometabolic diseases (20, 21). However, the molecular
changes in adipose tissue that promote these disorders are not
completely understood and, in particular, the specific role of
cardiac adiposity. Pericardial adipose tissue is ectopic fat in
the mediastinum, which is associated with poor metabolic and
cardiac health, especially in with type II diabetes mellitus (T2DM)
patients (22, 23). Pericardial adipose tissue is comprised of
two compartments. Epicardial adipose tissue (EAT) is defined
as the visceral fat deposited between the epicardium and
the pericardium. Paracardial adipose tissue (PAT) is the fat
deposited on the external surface of the pericardium within the
mediastinum (24). Growing evidence indicates that epicardial
adipose tissue (EAT) volume is positively associated with
coronary artery disease (23). The increase of EAT has been
associated with different cardiovascular risk factors (25) such as
type 2 diabetes mellitus, hypertension, and obesity, in isolation
or as part of the MeD (26–28). Growing evidence indicates that
EAT volume is positively associated with coronary artery disease
(29), but the mechanisms involved in this relationship remain
largely unknown. EAT is the visceral fat deposit over the heart,
located between the myocardium and the visceral pericardium
(21, 30). EAT is more than a simple fat storage depot. Indeed,
it is now widely recognized to be an extremely active endocrine
organ, producing cytokines, adipokines, and chemokines that
can be either protective or harmful depending on the local
microenvironment (31, 32). These functions highlight the
complex cellularity and crosstalk between EAT and neighboring
structures (21). EAT metabolism is uniquely regulated due to the
high basal rates of fatty acid uptake, insulin-induced lipogenesis,
and high fatty acid breakdown (33, 34). EAT may act as a local
energy store for cardiac muscle and has a protective role against
elevated levels of free fatty acid (FFA) in the coronary circulation
(35). Additionally, EAT could influence coronary atherogenesis
and myocardial function because there is no fibrous fascial layer
to impede the diffusion of FFA and adipokines between it and the
underlying vessel wall as well as the myocardium (34, 36). EAT
is also actively involved in lipid and energy homeostasis, with
EAT having a greater capacity for release and uptake of FFA (36–
38). FFA synthesis and rates of incorporation and breakdown are
significantly higher in EAT than in other fat deposits. However,
the amount and type of fatty acids stored could also play a
role in the onset and development of atherosclerosis (39). These
metabolites serve as direct signatures of biochemical activity,

Cardiovascular disease (CVD) is the leading cause of mortality
worldwide and remains the leading cause of death in the US
(1, 2). CVD encompasses a broad range of disorders of the
cardiovascular system, including coronary heart disease,
cerebrovascular disease, and peripheral artery disease.
Underlying them all is atherosclerosis (ATS)—a complex
disorder in which a host of different intrinsic and extrinsic
processes and factors contribute to the development of lesions
that eventually compromise normal vascular function (3). ATS
is an inflammatory disease of the arteries associated with lipid
and other metabolic alterations (4). Lipid dysregulation is a
well-known precursor to metabolic diseases (MeD), including
CVD. Risk factors for ATS and CVD, including age, sex, lipid
levels, smoking and blood pressure, are incorporated in risk
algorithms that are used to predict an individual’s absolute risk
for CVD in the general population (5). Although these risk
factors are useful to predict disease risk in populations, their
accuracy in predicting cardiovascular risk in individuals varies
considerably across populations (6). Mexican Americans have a
high prevalence of cardiovascular morbidity and mortality (5, 7).
The high risk for CVD in this ethnic group is partly explained by
a high propensity to MeD (5).
Evidence from epidemiological and lipidomic studies has
shown that specific lipoproteins and their constituent lipids
are important factors in the development of metabolic related
disorders (8–10), including CVD (11–13). The classical lipid
traits (such as HDL-C, LDL-C, and triglycerides), most
commonly examined in disease risk, are complex molecules
comprised of multiple lipid and protein components (14).
The lipidome is the total complement of these lipid species.
Even though these lipid measures are influenced by both
environmental and genetic factors, genetic variation is a
significant determinant with traditional plasma measures having
heritability of more than 50% (15, 16). Although CVD risk is
heritable and there have been a number of successes localizing
QTLs that influence disease risk, the genetic basis of this risk
is still relatively unknown. Quantitative endophenotypes that
are related to disease liability can offer more power for gene
localization/identification than dichotomous disease status and
thus serve as valuable phenotypes for disease gene identification.
Such endophenotypes, whose alterations precede disease, may
also be useful for early risk assessment. Measures of the human
lipidome represents a wealth of phenotypes that may be better
predictors of disease than the traditional clinical measures
(17). The biologically simpler nature of these individual species
suggests that they may reside closer to the causal action of genes,
making them valuable endophenotypes (18). Lipidomic studies
are helping to decipher the complex interactions between lipid
Frontiers in Cardiovascular Medicine | www.frontiersin.org

2

June 2022 | Volume 9 | Article 889985

Leandro et al.

Lipidomic Influences on Epicardial Fat

sequence (TR/TE = 2.44/1.22 ms, 25–30 cardiac phases, matrix
224 × 288, FOV 336 × 430 mm2 , pixel resolution 1.5 × 1.5 mm2 ).
Two 3-slice, cine, long-axis data sets in a left anterior oblique
and a four-chamber view were acquired. A stack of contiguous
short-axis slices, extending from the apex of the LV through the
atria, are then acquired with repetitive end expiration breathholds. Heart rate and EKG were monitored during the CMRI.
Pericardial fat scans were obtained in diastole using a shortaxis, single-shot steady-state free precession (IR-SFFP) sequence
with an inversion-recovery pre-pulse (TR/TE = 2.4/1.1 ms, slice
= 8.5 mm, 1.3 × 1.3 mm pixel, flip angle = 50◦ ) that covered
the complete left ventricle by long-axis stacks in a single breathhold. The inversion time (TI) was adjusted between 180 and
280 ms to obtain optimal enhancement of the epicardial fat. The
cvi42 image analysis package (Circle Cardiovascular Imaging
Inc., Calgary, AB) was used for assessment of pericardial fat.
Using long axis, 4-chamber images, thickness of pericardial fat
was measured at the cardiac mid-ventricular level laterally. For
analyses of pericardial fat, manual ROI contours were drawn
to define the EAT area by the region included inside contours
of the epicardium and pericardium. Summation of the pixels
included in the contours was recorded and multiplied by the perpixel dimensions to obtain an area measurement. For epicardial
fat volume determination, the area subtended by the manual
tracings is determined in each slice and multiplied by the slice
thickness and then summed to yield the fat volume. Visceral fat
was not examined in this study, it is measured in the abdomen
and our imaging protocol did not capture the abdominal region.

being, therefore, easier to correlate with quantitative plasma lipid
phenotypes. In this context, lipidomics has become a powerful
approach to mechanistically investigate how biochemistry relates
to clinical phenotype (40, 41). We concentrate on EAT because
it is a known adiposity-related risk factor for CVD, directly
related to heart function, but has been comparatively less studied
than more easily measured fat measures. However, there is a
scarcity of information on the interaction of plasma lipids and
CMRI EAT measures. Therefore, this study identifies plasma
lipidomic species associated with CMRI-derived measures of
epicardial fat, as a measure of CVD risk, in a cohort of Mexican
American individuals.

MATERIALS AND METHODS
Study Participants
The SAFHS began in 1991 and was initially designed to
investigate the genetics of CVD in Mexican Americans. The
SAFHS enrolled large, extended Mexican Americans families
residing in San Antonio, TX, and ascertainment occurred by
way of the random selection of an adult Mexican American
proband, without regard to disease. The enrollment procedures,
inclusion and exclusion criteria, and phenotypic assessments of
the study participants have been described in detail previously
(7, 42). This is an ongoing investigation, which has had four
phases of data collection over a 25-year period. The data and
samples used in this study were collected during the first phase of
data collection, occurring between 1992 and 1996. Blood samples
were collected from participants on their visit day using standard
procedures, and participants were fasted for 12 h. For plasma,
blood was collected in a K2-EDTA vacutainer, and the plasma
layer removed after centrifugation. Plasma was stored in 50 µL
aliquots at −80◦ C and has not been thawed post-collection. In
the current study, 200 individuals that have both lipidome profile
measures and CMRI-derived epicardial fat data were included. Of
these 200 SAFHS participants, 63% were female, and the sample
was aged between 18 and 83 (46.85 ± 16.23). Informed consent
was obtained from all participants before collection of samples.
The study conformed to the Declaration of Helsinki, and the
Institutional Review Boards of the University of Texas Health
Sciences Center at San Antonio and the University of Texas Rio
Grande Valley approved this study.

Lipidomic Profiling
Lipidomics was performed as described previously (43) with
modifications. Analysis of plasma extracts was performed on an
Agilent 1290 series HPLC system coupled to an Agilent 6495C
triple quadrupole mass spectrometer. Liquid chromatography
was performed on a dual column system with ZORBAX eclipse
plus C18 columns (2.1 × 100 × 1.8 mm, Agilent) heated
to 45◦ C. Mass spectrometry analysis was performed in both
positive and negative ion mode with dynamic scheduled multiple
reaction monitoring (MRM). The running solvent consisted of
solvent A: 50% H2O/30% acetonitrile/20% isopropanol (v/v/v)
containing 10 mM ammonium formate and 5 µM medronic acid,
and solvent B: 1% H2O/9% acetonitrile/90% isopropanol (v/v/v)
containing 10 mM ammonium formate. Gradient conditions are
presented in Supplementary Table S1, with alternating columns
for sample analysis (Pump A) and equilibration (Pump B).
The following mass spectrometer conditions were used: gas
temperature 150◦ C, gas flow rate 17 L/min, nebulizer 20 psi,
sheath gas temperature 200◦ C, capillary voltage 3,500 V and
sheath gas flow 10 L/min. Isolation widths for Q1 and Q3
were set to “unit” resolution (0.7 amu). Plasma quality control
(PQC) samples consisting of a pooled set of plasma samples
taken from six healthy individuals and extracted alongside the
study samples were incorporated into the analysis at 1 PQC
per 20 plasma samples. NIST 1950 SRM sample (Sigma) was
included as a reference plasma sample, at a rate of 1 per 40
samples. Relative quantification of lipid species was determined
by comparison to the relevant internal standard. Lipid class total

Epicardial Fat Tissue Measurement by
Cardiac Magnetic Resonance Imaging
Cardiac imaging was performed on a 3.0 Tesla MR scanner
(TIM Trio; Siemens, Erlangen, Germany) with a 6-channel
anterior matrix torso coil combined with posterior spine-coil
elements producing an aggregate of 12 data channels. For MRI
of the abdominal aorta, an additional 6-channel anterior matrix
receiver coil ensures full coverage. All subject assessment, blood
collection, and imaging were performed at the Research Imaging
Institute at UTHSCSA. Before each session, a standard quality
control phantom was imaged. Cardiac morphology and function
were determined after initial anatomical localizer images. High
temporal resolution cine MR imaging with prospective gating
was performed, using a balanced, steady-state free precession

Frontiers in Cardiovascular Medicine | www.frontiersin.org

3

June 2022 | Volume 9 | Article 889985

Leandro et al.

Lipidomic Influences on Epicardial Fat

unconstrained regression models to yield an LRT test that is
distributed as χ2 variate with one degree of freedom. The
significant lipid classes and species were defined using a False
Discovery Rate (FDR) smaller than 0.05 calculated using the
empirical p-value distribution.

TABLE 1 | Characteristics of the study population.
Parameters

Average

Minimum

Maximum

Sex
Male (n-%)

74 (37)

–

–

Female (n-%)

126 (63)

–

–

Age (years old)

46.85 ± 16.23

18

83

Male

45.18 ± 17.10

19

77

Female

47.83 ± 15.62

18

83

Education (years)

12.39 ± 2.94

1

22

Height (cm)

161.96 ± 9.54

127.00

186.50

Weight (Kg)

84.44 ± 18.76

39.92

163.29

BMI

32.158 ± 6.40

17.51

51.25

Waist (cm)

101.56 ± 14.82

63.00

149.00

Systolic BP-Avg (mmHg)

125.24 ± 16.82

96.00

191.67

Diastolic BP-Avg (mmHg)

76.24 ± 11.58

40.33

142.00

Diabetes mellitus (n-%)

43 (21.5%)

–

–

Hypertension (n-%)

73 (36.5%)

–

–

RESULTS
For this study, we had a cohort of 200 Mexican American
individuals with lipidomic profiles and CMRI-derived epicardial
fat volume measures. Baseline demographic and clinical status of
these 200 participants is shown in Table 1. The mean age of the
participants was 46.85 ± 16.23 years old, 74 (37%) were male,
73 (36.5%) had hypertension, and 43 (21.5%) had type 2 diabetes
(T2D). Mean body mass index (BMI) was 32.158 ± 6.40 kg/m2 .
There were no differences in BMI, prevalence of hypertension or
T2D between men and women, however the prevalence of T2D
in women was 2.5 times higher than in men.
EAT volume was evaluated with good reproducibility in
our study. Average EAT volume was 7.95 ± 3.81 cm3 in
all individuals. EAT volume was not significantly different in
hypertensive vs. normotensive subjects (8.85 ± 3.73 cm3 vs.
7.45 ± 3.74 cm3 , p = 0.6699); nor was it significantly different
between subjects with and without T2D (9.32 ± 4.0 cm3 vs. 7.6
± 3.65 cm3 , p = 0.2812). In this study, the mean EAT volume
was 7.95 ± 3.81 cm3 , ranging from 0.94 to 19.88 cm3 . The ageadjusted difference in EAT volume between males and females
was trending toward significance (8.0 ± 3.74 cm3 vs. 7.92 ± 3.84
cm3 , p = 0.0561). After analyzing the sample by increasing age,
we observed a significant increase in EAT volume with increasing
age, in both males and females (p < 2.5 × 10−6 ) (Figure 1). There
was no evidence for any interactions of sex and age. Additionally,
there was no significant evidence for a non-linear relationship
with age.
Quantitative genetic analysis revealed that EAT is under
substantial genetic control in this population. The estimated
heritability was 0.86 ± 0.16, 95% CI = (0.55, 1.0), p = 1.8 ×
10−6 . To our knowledge, this is the first study to evaluate the
relative importance of additive genetic factors for this phenotype
in humans.
To optimize the number of statistical tests being performed,
we first conducted our analyses at the level of lipid class. We
analyzed the association of 48 lipid classes listed in Table 2 with
epicardial fat volume. Using multivariable regression models
performed in SOLAR and controlling the false discovery rate
(FDR) using the Benjamini-Hochberg method (45–47), we
found that nine lipid classes were statistically associated with
EAT volume (Table 3). The classes were triacylglycerol (TG),
hydroxylated acylcarnitine (AC-OH), deoxyceramide (Cer(m)),
alkyldiacylglycerol (TG(O)), ubiquinone, diacylglyceride (DG),
dihydroceramide (dhCer), phosphatidylinositol (PI) and
phosphatidylglycerol (PG), respectively by lowest to highest FDR
< 0.05. It is worth noting that several of the classes associated
with EAT volume were previously implicated in the pathogenesis
of T2D, insulin resistance and consecutively in CVD risk.

n, number of participants; %, percentage; cm, centimeters; Kg, Kilograms; mmHg,
millimeters of mercury.

concentrations were calculated as the sum of individual lipid
species concentrations, except in the case of two lipid classes,
triacylglycerol (TG) and alkyldiacylglycerol, TG(O), where we
measured both neutral loss (NL) and single ion monitoring
(SIM) transitions. We used the more quantitatively accurate
but less structurally resolved (SIM) species concentrations for
summation purposes when examining lipid totals, while their
(NL) counterparts were used for associations.

Statistical Analysis
Initially, we estimated epicardial fat volume content heritability
using a quantitative genetic variance component decomposition
approach as implemented on SOLAR (version 8.1.1) (44). We
used a linear mixed model  = 2φσG2 + Iσe2 where, Ω is the
total phenotypic covariance matrix of a trait, φ is the matrix
of kinship coefficients, I is the identity matrix, σG2 is additive
genetic variance, and σe2 is residual environmental variance.
All the models were adjusted for the following covariates:
age, age2 , sex, age × sex, and age2 × sex. We do not use
medication as a covariate. This cohort is a traditionally medically
underserved population and very few of them are taking lipid
lowering or other relevant medications (we collect medications
at all subject visits). When we correct for medications, the
observed results are not qualitatively changed. Heritability was
defined as the proportion of phenotypic variance explained by an
additive genetic model. We tested the association of each lipid
species and lipid classes with epicardial fat volume by means of
LRT (Likelihood Ratio Test) comparing two models with and
without the presence of a lipid class/species while allowing for
residual non-independence due to underlying genetic factors
which induce correlations between related individuals. Statistical
significance of a given lipid association with epicardial fat
was tested by constraining the regression coefficient to 0
and comparing the log-likelihoods of the constrained and
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FIGURE 1 | Distribution of epicardial fat volume in males (left plot) and females (right plot) by age group.

clinical lipid markers. We examined the associations of the
clinical lipid measures and EAT in this sample and found
the associations to be p = 0.01 for total cholesterol, p
= 0.008 for calculated LDL, p = 0.0008 for HDL and p
= 4.32 × 10−6 for triglyceride levels. Triglyceride levels
were the only clinical lipid measure nearing the level of
significance observed in the lipidome measures, particularly
for the triacylglycerol (TG) species. This is to be expected
as the triglyceride measure is the sum composition of all
triacylglycerol species measured in our analysis. In contrast
the many other species of ceramide, deoxyceramide and
phospholipid species containing polyunsaturated fatty acids are
not strongly correlated with clinical lipid measures and so are
providing independent information about EAT. For standardized
phenotypes, p-values are directly related to observed effect
sizes (e.g., residual correlation). Therefore, the improved pvalues directly relate to larger associations and hence greater
biological significance.

We next examined the association of lipid species with EAT
volume using SOLAR, analyzing 799 lipid species from the 48
classes. After appropriate adjustments described in methods,
our plasma lipidome analyses showed that 135 lipid species
belonging to 19 lipid classes were significantly associated with
EAT volume with an FDR <0.05 as shown in Figures 2,
3. The list of lipid species with their respective average
concentration, concentration range and number of lipid species
within the class with an FDR < 0.05 are shown in Table 2.
The full list of lipid classes and species with p-value, beta
coefficient of regression (SDU) and FDR analysis are shown in
Supplementary Tables S2, S3, respectively.
After appropriate adjustment for the effective number of
tests in our plasma lipidome analyses in SOLAR, the EAT
volume was associated with the increase of 131 lipids and
decrease of 4 individual lipid species. The strongest associations
observed were with two deoxyceramide species Cer(m18:1/18:0)
and Cer(m18:1/20:0) with beta coefficient of regression of
0.40 and 0.34 and p = 1.63 × 10−4 and p = 4.44 × 10−3 ,
respectively. This association demonstrated, in our study, that
a larger EAT volume was correlated with an increased plasma
concentration of deoxyceramide. The 20 species of lipids with
the most significant p-values are described in Table 3 and
shown in Figure 3. Interestingly, these lipid species belong
to only 3 classes of lipids: deoxyceramide, triacylglycerol
and phosphatidylinositol. In addition, only species from
an extra 6 classes of lipid showed significant associations
(Table 3). These additional species belong to the classes:
hydroxylated acylcarnitine, alkyldiacylglycerol, ubiquinone,
diacylglycerol, dihydroceramide, and phosphatidylglycerol.
Additionally, we observed substantial heterogeneity of effects
within 10 lipid classes (cholesterol ester (CE), ceramide
(Cer(d)), deoxyceramide (Cer(m)), dehydrodesmosterol ester
(deDE), lysophosphatidylcholine (LPC), phosphatidylcholine
(PC), phosphatidylethanolamine (PE), phosphatidylinositol,
sphingomyelin (SM) and lysophosphatidylinositol (LPI).
Interestingly, one class (PC) showed both significant increasing
(three species) and decreasing (one species) associations with
EAT volume, suggesting the potential for dynamic feedback
within class, most likely driven by the fatty acids.
The associations observed with the plasma lipidome measures
were more significant than those observed for standard

Frontiers in Cardiovascular Medicine | www.frontiersin.org

DISCUSSION
Given that CVD is the leading cause of death in the US
and much of the world, the identification of novel risk
factors is essential to help alleviate the substantial health and
economic burden. So, novel insights into biological mechanisms
that predispose individuals to CVD hold the promise of a
significant reduction in this considerable economic burden.
It is well-known that a relationship exists between lipid
variation and CVD, but the mechanisms are unclear. Modern
genomic technologies can be exploited to rapidly identify
genes involved in disease susceptibility. However, the costeffectiveness of such exploratory endeavors can be greatly
augmented if genetic basis to a phenotype is strongly suspected.
A recent article by Blanco-Gomez et al. (48) explains nicely
the complex interplay between phenotypes and disease at
the global level where most major diseases are considered
complex phenotypes and are the consequence of intermediate
phenotypes causally related to or involved in their pathogenesis.
These intermediate phenotypes can go all the way down to
the tissue, transcript, and ultimately to genomic level (48).
Therefore, intermediate phenotypes such as those derived by
CMRI, and lipid profiling as described in this study could
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TABLE 2 | Lipid classes assessed by targeted lipidomics: concentration (pmol/mL), range of concentration (maximum and minimum, pmol/mL) and associations with EAT
volume.
Lipid class name

Class abbreviation

Concentration

Minimum

Maximum

No. of species

No. of species*

Acylcarnitine

AC

780.16

277.75

1,897.03

28

4

Alkenylphosphatidylcholine (P)

PC(P)

60,236.05

25,391.79

128,139.69

30

0

Alkenylphosphatidylethanolamine (P)

PE(P)

63,098.10

22,049.00

157,529.53

53

0

Alkyldiacylglycerol

TG(O)

2,225.81

526.33

17,015.81

20

12

Alkylmonoacylglycerol

DG(O)

1,931.96

442.86

5,054.66

2

0

Alkylphosphatidylcholine

PC(O)

71,020.49

35,800.19

125,404.02

34

0

Alkylphosphatidylethanolamine

PE(O)

3,595.49

1,510.84

7,742.28

14

0

Bile acid

BA

Ceramide

Cer(d)

835.86

115.07

6,533.81

2

0

18,222.47

5,289.50

35,327.51

47

8

Ceramide-1-phosphate

C1P

5.95

0.96

17.30

1

0

Cholesteryl ester

CE

3,481,161.11

1,801,143.14

6,008,721.67

27

2

Dehydrocholesterol ester

DE

18,330.58

7,819.13

61,318.78

6

1

Dehydrodemosterol ester

deDE

360.13

23.77

5,225.42

2

0

Deoxyceramide

Cer(m)

1,337.83

258.05

7,013.12

11

8

Diacylglycerol

DG

113,181.88

37,769.76

432,782.54

26

14

Dihexosylceramide

Hex2Cer

4,007.89

1,549.11

7,162.76

10

0

Dihydroceramide

dhCer

375.41

149.99

777.79

6

2

Dimethyl-cholesteryl ester

dimethyl-CE

24,635.70

7,573.76

71,080.92

4

0

Free cholesterol

COH

747,839.09

428,202.30

1,178,895.10

1

0

Free fatty acid

FFA

395,032.85

205,376.16

683,429.45

17

0

GD1 ganglioside

GD1

7.36

1.84

14.66

1

0

GM1 ganglioside

GM1

19.03

0.61

41.33

1

0

GM3 ganglioside

GM3

3,121.22

1,384.39

5,629.32

7

0

Hydroxylated acylcarnitine

AC-OH

23.52

9.22

46.06

8

5

Lysoalkenylphosphatidylcholine (P)

LPC(P)

772.16

198.42

1,508.36

6

0

Lysoalkenylphosphatidylethanolamine (P)

LPE(P)

310.79

102.04

745.05

4

0

Lysoalkylphosphatidylcholine (LAF)

LPC(O)

3,094.26

1,333.28

4,890.32

10

0

Lysophosphatidylcholine

LPC

219,759.08

115,804.17

370,825.40

61

3

Lysophosphatidylethanolamine

LPE

6,563.27

3,124.24

12,965.85

14

0

Lysophosphatidylinositol

LPI

1,519.93

844.58

2,776.85

7

2

Methyl-cholesteryl ester

methyl-CE

37,950.13

10,953.57

129,335.37

5

0

Methyl-dehydrocholesteryl ester

methyl-DE

2,929.83

622.81

9,579.89

2

0

Monohexosylceramide

HexCer

3,212.20

911.79

6,392.99

14

0

Oxidized lipids

OxSpecies

6,579.85

2,681.95

13,155.84

6

1

Phosphatidic acid

PA

76.43

40.32

164.48

5

0

Phosphatidylcholine

PC

1,737,177.86

1,048,144.69

2,398,255.66

90

4

Phosphatidylethanolamine

PE

40,484.40

15,353.48

95,420.85

37

5

Phosphatidylglycerol

PG

475.99

134.61

1,170.81

3

1

Phosphatidylinositol

PI

215,820.31

60,717.32

370,648.86

27

9

Phosphatidylinositol monophosphate

PIP1

628.26

85.24

1,380.75

1

0

Phosphatidylserine

PS

6,981.00

354.86

23,312.22

7

0

Sphingomyelin

SM

342,792.34

190,455.47

557,621.10

47

2

Sphingosine

Sph

494.68

214.47

1,108.70

1

0

Sphingosine-1-phosphate

S1P

2,072.79

1,120.77

4,252.17

4

0

Sulfatide

SHexCer

Triacylglycerol (NL)

TG

565.90

269.16

1,082.07

6

0

1,742,464.14

450,098.99

7,784,888.83

77

51

Trihexosylcermide
Ubiquinone

Hex3Cer

1,580.81

739.32

2,721.76

6

0

Ubiquinone

2,069.76

508.35

4,924.12

1

1

799

135

Total

Numeric values are given as average and range. No., number; P, Plasmogen; LAF, lysoplatelet activating factor. *No. with p < 0.05 designates the number of lipids significantly associated
with EAT volume measurement at the 0.05 level of false discovery rate (FDR) under adjustment for age, sex and their interactions.
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TABLE 3 | Species and classes of lipid with the lowest false discovery rate p-values in our study.
Lipid classes
Lipid classes name

Lipid abbreviation

Triacylglycerol

TG

3.23E-04

0.3062

6.97E-03

Alkyldiacylglycerol

TG(O)

1.07E-04

0.2620

1.24E-03

Hydroxylated acylcarnitine

AC-OH

1.28E-03

0.2415

1.34E-02

Deoxyceramide

Cer(m)

2.48E-03

0.2698

2.07E-02

Ubiquinone

Ubiquinone

3.81E-03

0.2465

2.79E-02

p-value

Beta (SDU)

FDR

Diacylglycerol

DG

4.09E-03

0.2481

2.85E-02

Dihydroceramide

dhCer

5.01E-03

0.2331

3.17E-02

Phosphatidylinositol

PI

6.33E-03

0.2349

3.59E-02

Phosphatidylglycerol

PG

8.38E-03

0.2232

4.39E-02

Lipid species
Lipid species name

Lipid class

p-value

Beta (SDU)

FDR

Cer(m18:1/18:0)

Cer(m)

1.84E-07

0.4000

1.63E-04

Cer(m18:1/20:0)

Cer(m)

2.23E-05

0.3463

4.44E-03

TG(50:1)[NL-16:0]

TG

2.20E-05

0.3450

4.44E-03

TG(50:1)[NL-18:1]

TG

3.37E-05

0.3405

4.44E-03

TG(50:2)[NL-18:2]

TG

3.18E-05

0.3393

4.44E-03

TG(49:1)[NL-17:1]

TG

2.89E-05

0.3366

4.44E-03

TG(51:2)[NL-17:1]

TG

5.23E-05

0.3354

5.17E-03

TG(54:2)[NL-18:0

TG

6.36E-05

0.3205

5.17E-03

TG(54:6)[NL-20:4]

TG

5.45E-05

0.3069

5.17E-03

TG(53:2)[NL-17:1]

TG

8.04E-05

0.3232

5.76E-03

PI(16:0/16:1)

PI

8.46E-05

0.2901

5.76E-03

TG(51:2)[NL-17:0]

TG

1.13E-04

0.3252

6.22E-03

TG(54:5)[NL-20:4]

TG

1.12E-04

0.2972

6.22E-03

PI(16:0/20:4)

PI

1.08E-04

0.2935

6.22E-03

TG(50:2)[NL-16:1]

TG

1.54E-04

0.3199

6.66E-03

TG(50:3)[NL-16:1]

TG

1.65E-04

0.3182

6.66E-03

TG(52:1)[NL-18:1]

TG

1.64E-04

0.3117

6.66E-03

TG(48:1)[NL-16:1]

TG

1.84E-04

0.3057

6.66E-03

TG(52:2)[NL-18:2]

TG

1.88E-04

0.3028

6.66E-03

TG(50:6)[NL-20:4]

TG

1.40E-04

0.2840

6.66E-03

SDU, standard deviation units.

lie closer to the genomic level and ultimately the causal
action of genes. So, the identification of novel lipid-related
endophenotypes that are genetically correlated with CVD
offers the potential to discover biomarkers which will quickly
lead us to the identification of novel CVD treatments and
ultimately preventatives.
The most common risk factors for CVD are deleterious
lipid concentrations, obesity, hypertension, and smoking.
Additionally, significant health disparities exist in CVD in
some minority groups, in both health outcomes and quality
of care. Hispanic populations have a significantly worse CVD
risk profile, however the prevalence of some CVDs, such as
coronary heart disease, are lower than in other ethnic groups,
a phenomenon known as the Hispanic Paradox (49). Hispanic
individuals face significant socioeconomic challenges, and they

Frontiers in Cardiovascular Medicine | www.frontiersin.org

tend to have low rates of disease awareness and health insurance
and are less likely to seek treatment. A recent American
Heart Association statement on the health burden of CVD in
Hispanics acknowledges insufficient understanding of Hispanic
heart health and supports the need for more Hispanic CVD
research (49, 50). The work of our group in Mexican American
individuals, has demonstrated a role for these lipid species and
the measurement of CMRI-derived phenotypes in CVD disease
risk. Our results provide information that lipid measures (which
are significantly associated with common complex diseases)
and the use of the extended pedigrees of Mexican Americans,
along with our novel lipidomic approach and CMRI-derived
measures are extremely powerful and cost-effective tools for the
identification of the relationship between lipid metabolism and
CVD risk.
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FIGURE 2 | Tornado plot of plasma lipidome associations with EAT volume. The figure shows all lipid species within their specific classes and the degree of
association with EAT volume (FDR). Each dot represents a lipid species and each color a lipid class. The dotted line represents an FDR of 0.05. All species above the
dotted line were considered as significantly associated with epicardial fat volume.

Heritability of coronary heart disease is estimated to be up
to 60% and comes from a variety of family and twin studies
(51). CMRI phenotypes, including measures of left ventricle
(LV) mass, volume and function, demonstrate high heritability

Frontiers in Cardiovascular Medicine | www.frontiersin.org

(LV mass heritability ranges from 15 to 84%) (52). In our
study, the heritability of epicardial fat volume was 86.29% (pvalue = 1.8 × 10−6 ± 0.1617). This is a validation that EAT
volume is significantly genetically regulated and demonstrates
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FIGURE 3 | Plasma lipidome associations with EAT volume [beta coefficient of regression (SDU)]. The figure shows significant increases and decreases in lipid levels in
19 classes of lipids with species having an FDR < 0.05 (indicated by the red dots). Each dot represents a lipid species within the specific lipid class.

increases in epicardial fat, as a component of obesity,
may provide one of the links between obesity, coronary
atherosclerosis and consequently CVD. Fat in the heart resides
in three distinct depots: epicardial, pericardial and intracellular
fat. Epicardial fat is located on the surface of the heart especially
around the epicardial coronary vessels. It can extend into the
heart and intersperse within myocardial muscle fibers (35).
There is a significant direct relationship between the amount
of epicardial fat and general body adiposity (visceral adiposity)

the power for identification of intermediate phenotypes in
CVD prevention. This study focused on cardiac imaging and
lipidomic profile with the ultimate aim of identifying possible
lipid phenotypes influencing CVD risk. Focusing on these
intermediate phenotypes may direct us more rapidly to CVD risk
gene identification.
The fundamental mechanisms potentially responsible
for cardiovascular events in overweight individuals remains
uncertain. Thus, it is important to ask the question whether

Frontiers in Cardiovascular Medicine | www.frontiersin.org
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group of lipids accounting for a good proportion of total
lipids in plasma. Triacylglycerol (TG) is the most abundant
lipid class and comprises the bulk of storage fat in tissues.
Monoacylglycerol (MG) and diacylglycerol (DG) represent
intermediates in the biosynthesis and hydrolysis of TG and
function as second messengers in signal transduction processes
(70, 71). It has previously been shown that the breakdown
and synthesis of triglycerides by DG and MG have a causal
effect on CVD risk (13). Sphingolipids are wide range of
complex lipids and constitute several hundreds of different
species, including ceramides, which function as a precursor
for complex sphingolipids (72, 73). Sphingolipids and their
precursors, may be involved in the pathogenesis of CVD through
multiple pathways including inflammation (74), atherosclerosis
(75), and apoptosis (76). Kulkarni et al. have demonstrated
a role for diacylglycerols, with four species (each containing
palmitic acid) showing significant genetic correlations with
hypertension (9). Additionally, Mamtani et al. showed consistent
association of ceramides (Cer(d)) with waist circumference
where levels were significantly higher in diabetics compared to
non-diabetics (p = 2.5 × 10−7 ) (10). Alshehry et al. showed that
monohexosylceramide (HexCer), dihexosylceramide (Hex2Cer)
and lysoalkylphosphatidylcholine (LPC(O)) were associated
with cardiovascular events and HexCer and Hex2Cer with
cardiovascular death (68). Alshehry et al. found that five
species of lipids containing polyunsaturated fatty acids (PUFAs),
including phospatidylcholine (PC,) alkenylphosphatidylcholine
(PC(P)) and triacylglycerol were inversely associated with CVD
risk. In our results, we show that two of these lipids (PC and TG)
are associated with epicardial fat volume.
It is now well-established that ceramide metabolism is altered
in the context of type 2 diabetes (T2D) and obesity which
are both linked to CVD (77, 78). In fact, higher plasma
ceramide levels have been associated with visceral obesity, nonalcoholic fatty liver disease, and T2D, which are also predictors
of CVDs (79–84). There is an interplay between the level
of ceramides in the plasma/tissues and disease development.
Hepatocellular ceramides stimulate fatty acid uptake (85) and
decrease glucose uptake (85, 86), which enables hepatocytes to
favor fatty acids over glucose as a preferred energy source and
leads to NAFLD (85). In our study, eight of the 47 ceramide
lipids were significantly associated with EAT volume. The most
significant species within the Cer(d) class with both FDR value
of 6.97x 10−3 was Cer(d18:1/18:0) and Cer(d19:1/18:0) (p-value
3.31 × 10−4 ). Several studies have found these species to be
associated with CVD (82–84) and that ratios of long chain
ceramide species Cer(d18:1/16:0) and Cer(d18:1/18:0) were more
strongly correlated with negative cardiovascular outcomes than
ratios of very long chains of ceramide species Cer(d18:1/24:0)
(84). The Cer(d) species associated with EAT volume in our
cohort were only long chain ceramide species. Laaksonen et al.
(84) found that the ratios of Cer(d18:1/24:0)/Cer(d18:1/16:0)
and Cer(d18:1/24:0)/Cer(d18:1/16:0) negatively correlate with
coronary heart disease and mortality, and Anroedh et al. found
Cer(d18:1/20:0) to be associated with CVD event and death
(87). This last lipid species was positively associated with EAT
volume in our cohort with (SDU 0.3463; FDR 4.44 × 10−3 ;

as demonstrated in clinical imaging studies by Rabkin (27, 35).
Several lines of evidence support a role for epicardial fat in
the pathogenesis of coronary artery disease: first, due to the
close anatomic relationship between epicardial fat and coronary
arteries (35, 53); second, due to the positive correlation between
the amount of epicardial fat and the presence of coronary
atherosclerosis (54, 55) and third, due to the ability of adipose
tissue to secrete hormones and cytokines that modulate coronary
artery atherothrombosis (31). Thus, epicardial fat may be an
important factor responsible for cardiovascular disease in obesity
(25, 33).
Genetic and epidemiological studies have greatly improved
our understanding of pathophysiology underlying the complex
of CVDs and have identified several risk factors. Amongst the
well-recognized predisposing factors, lipid metabolism plays a
central role in the development of CVDs (56, 57). Since the
landmark publications from the Framingham study (58), plasma
lipids have been recognized as important predictors of future
CVD events (59). To assess these events, plasma lipids are
routinely monitored by profiling total cholesterol, triglycerides,
high-density lipoprotein cholesterol (HDL-C) and low-density
lipoprotein cholesterol (LDL-C) (referred as “traditional lipids”).
Efforts to understand the role of lipids in CVD pathophysiology
had largely focused on these traditional lipids, and to some extent
on free fatty acids and lipoproteins. However, human plasma
consists of thousands of functionally and chemically diverse
molecular lipid species (41, 60). Nevertheless, tremendous
advancements in the field of lipidomics has facilitated these
efforts to unravel the metabolic dysregulation in complex lipidrelated disorders, particularly in CVDs and for the identification
of predictive biomarkers beyond traditional lipids (61, 62). Lipids
are of central importance for the bioenergetic metabolism of the
heart and in the healthy heart, fatty acids (FAs) account for 60–
90% of ATP production while glucose provides the remainder
(63, 64). When damaged, the heart shifts away from lipids
toward a greater reliance on glycolysis, ketone body oxidation,
amino acids, and lactate as sources of energy (63, 65). This
shift in cardiac metabolism and identification of the metabolic
pathways involved remains a challenge and consequently so too
does the translation of these metabolic findings to the clinical
setting for improved or novel diagnostic/prognostic biomarkers
(17). That interdependence of metabolites results in a disease
signature which can be used to more precisely identify or
predict disease states, which represents the closest link to the
phenotype. The biologically simpler nature of these individual
lipid species suggest that they may reside closer to the causal
action of genes, making them valuable endophenotypes (18).
Even though changes in the levels of numerous metabolites
have been shown to occur in the failing heart (BCAA, lactate,
ketones), specific lipid metabolites appear to consistently change
in metabolomic profiles of CVD patients, namely sphingolipids,
phospholipids, glycolipids, cholesterol esters, fatty acids and
acylcarnitines (63).
Epidemiological and lipidomic studies has shown that specific
lipoproteins and their constituent lipids are important factors
in the development of metabolic related disorders (9, 10,
66) and CVD specifically (67–69). Glycerolipids are a large
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p-value 2.23 × 10−5 ). Another more recent study found that
serum sphingolipids are markers of coronary artery disease,
independent of cholesterol (88), further solidifying the strong
correlation between these species and negative cardiac outcomes.
These dual (positive or negative) ceramide actions may be due
to manipulations of the de novo ceramide synthesis pathway
suggesting that certain ceramide species are deleterious, whereas
others are beneficial (77, 89–91). Those containing the C16 or
C18 acyl chain (77, 89, 90) and a double bond (i.e., ceramides,
not dihydroceramides) (92) in the sphingolipid backbone are
particularly harmful. Thus, plasma ceramide levels can be used
as clinical biomarkers to predict risk of cardiovascular death.
Another lipid class that we found to be significantly associated
with EAT volume was dihydroceramide (dhCer). This lipid is
the precursor of ceramide in the de novo synthesis pathway.
Ceramides and their derivates are involved in many, if not all,
essential cellular process such cell growth, cell adhesion and
migration, senescence, apoptosis, inflammation, immune system
and angiogenesis (73, 93). Ceramide synthesis and accumulation
are influenced by multiple factors, which include excessive
supply of substrates, systemic inflammation, oxidative stress
and the microbiome (94). Therefore, the many roles played by
ceramides and derivates in cardiometabolic health and diseases
are associated with this connection between excessive supply of
lipids and inflammation (95). The ceramide family of species
has been reported to have a strong correlation with CVD risk
in the literature. We found that 2 of 6 measured dhCer species
(dhCer(d18:0/24:1) and dhCer(d18:0/22:0)) were significantly
associated with EAT volume. Other authors have reported the
existence of a strong correlation between CVD and increased
dihydroceramide levels. Elevated levels of dihydroceramides have
been found in atherosclerotic plaques (75). The role this increase
in dihydroceramides plays in plaque stability is still debatable,
since the extracellular addition of dihydroceramides to human
aortic smooth muscle cells did not cause apoptosis, whereas
addition of ceramides did (75). One atypical sphingolipid
(deoxyceramide -Cer(m)) was also associated with EAT in
our study, with the two most significant FDR results. These
ceramides are neurotoxic sphingolipids which are formed by
the enzyme serine palmitoyltransferase (SPT). Pathologically
elevated Cer(m) levels were found in patients with MetS or
T2D (96–99). The mechanisms which underlie this increased
Cer(m) formation in metabolic disorders is not understood.
Low but detectable Cer(m) levels are generally found in
plasma - also of healthy individuals. However, patients with MetS
or T2D have significantly elevated plasma Cer(m) levels (98,
99). These observations may reflect an underlying interaction
between the severity or control of T2D in this population and
cardiovascular risk.
The glycerophospholipids, also known as phospholipids, are
the major structural component of cell membranes and are
involved in various biological processes including inflammation
(72). It has been shown that there is a marked difference in
the lipidome of adipose tissues depending on their epicardial
or subcutaneous origin (SAT) (21). Barchuk et al. found a
specific enrichment in sphingolipids, phosphatidylcholine (PC),
phosphatidylethanolamine (PE), and phosphatidylethanolamine
plasmalogens (PE(P)) in EAT compared with SAT. They
Frontiers in Cardiovascular Medicine | www.frontiersin.org

observed that EAT was rich in PC and in PE. Our results
corroborate this finding, identifying a total of 127 different
species of PC and PE, accounting for almost 16% of total
lipid profile. From those, a total of nine lipids (4 PC and
5 PE) were associated with EAT in our cohort. Barchuk
et al. (21) also observed a specific lipidomic signature of
EAT in coronary artery disease (CAD) patients, identifying
97 lipid species that discriminated patients with and without
CAD. They also observed that patients with CAD exhibited
more ceramides, diacylglycerides, monoacylglycerides, and less
unsaturated triacylglycerols in their EAT. This group also
found that that the EAT lipidome was independent to that
of SAT, possibly indicating a specific high metabolic activity,
or a beige associated phenotype. Although we did not
evaluate cardiovascular disease between the individuals with
high EAT in our cohort, the lipid profile associated with
EAT was basically the same as found by Barchuk et al.,
where the majority of the lipids associated with EAT were
from sphingolipids (ceramides, dihydroceramides, 1-deoxysphingolipds, sphingomyelins) and glycerolipids (DG and TG)
(21). Our results suggest that saturated fatty acids (FAs) on the
TG species show strong association with EAT. The majority
of the FAs on the top 28 TG species significantly associated
with EAT were saturated. Stegemann et al. in a populationbased study, identified a specific cluster of triacylglycerol species
with saturated and monounsaturated acyl chains as most
consistently associated with CVD (100). The association between
saturated/monounsaturated fatty acids and cardiovascular risk
was also evident in or study. Recently, Tomasova et al., found
a higher content of phosphatidylcholine and decreased level of
phosphatidylethanolamine (18:0/20:4) in EAT compared with
SAT (101). Although our study didn’t measure SAT volume for
comparison with EAT, we did find high numbers of PCs and
PEs associated with EAT volume, where high concentrations of
these lipids was observed in individuals with high epicardial
volume. These observations may reflect an underlying interaction
between the severity or control of T2D and CVD risk.
These associations suggest that there are multiple factors
that influence lipid homeostasis and presumably CVD risk.
The effects of these lipid species on epicardial fat volume,
after adjustment for established risk factors, likely reflects both
environmental and genetic factors not currently considered in
CVD risk.

LIMITATIONS
Some limitations of the present study need to be considered. First,
our findings should be seen as indicative and need confirmation
by replication in independent cohorts. All study participants were
Mexican Americans, so, it is not possible to generalize these
results to other ethnic groups. Future studies need to investigate
the similarities and differences of lipid associations and CVD risk
in different ethnic populations. Second is the limitation of all
lipidomic studies where the coverage is incomplete. In this study,
we used a targeted approach that has enabled us to measure 799
lipid species from 48 different lipid classes, providing a broad,
but still incomplete, coverage of the lipidome. Third, the high
variance associated with lipidomic measurements can reduce
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and classes. PM was responsible for overseeing the lipidomic
profiling, interpretation of the data, and wrote sections of the
manuscript. JB directs the SAFHS cohort and was responsible
for overseeing the statistical analysis and wrote sections of the
manuscript. MA, MK, and VD were responsible for the statistical
analyses in SOLAR and for generating some of the figures. JC
directed the study and wrote sections of the manuscript. All
authors contributed to manuscript revision, read, and approved
the submitted version.

the strength of observed associations. Lastly, all inferences in
this study are based on cross-sectional data. The associations
therefore do not automatically imply a causal role of plasma
lipid species in the pathogenesis of CVD. The main goal of
the study was to query the existence of potential correlations
in EAT volume and specific lipid species for prediction of
CVD risk.

CONCLUSION

FUNDING

In conclusion, using a novel integrative approach by combining
plasma lipidomics and CMR imaging of epicardial fat volume,
we have shown that specific lipid abnormalities correlate with
cardiovascular disease risk. Our findings should be considered
as preliminary and the possible role of these triacylglycerols
and/or ceramides in the development or prevention of CVD
warrant further investigations. On a general level, our study
also provides a framework for linking plasma lipidomic markers
not only with clinical endpoints, but also with the more subtle
intermediate phenotypes, as derived from medical imaging of
potential pathophysiological relevance.
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